News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Viamet Pharmaceuticals Expands Phase 2 Clinical Program With Novel Antifungal Agent VT-1161


9/24/2013 9:48:20 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Viamet Pharmaceuticals, Inc. announced today the expansion of the phase 2 clinical program for the novel antifungal agent VT-1161. The initial phase 2 study previously announced is designed to evaluate the safety and efficacy of VT-1161 in the oral treatment of acute vulvovaginal candidiasis (VVC). A second phase 2 clinical study has been initiated to evaluate the safety and efficacy of VT-1161 in the oral treatment of moderate to severe interdigital tinea pedis, commonly called athlete’s foot. Both studies are being conducted at leading clinical centers in the United States. VT-1161 has been shown in preclinical studies to potently inhibit, in a safe and selective manner, a wide range of fungal pathogens causing human disease. In previous phase 1 clinical studies, VT-1161 demonstrated good safety, tolerability and pharmacokinetics.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES